Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05480241
Other study ID # EPInAP
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 1, 2022
Est. completion date December 31, 2024

Study information

Verified date July 2022
Source Centro Hospitalar e Universitário de Coimbra, E.P.E.
Contact Marta Gravito-Soares, MD
Phone (+351)239400483
Email ms18498@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute pancreatitis represents an acute inflammatory process of the pancreas, which undergoes local and systemic complications, associated with non-negligible morbidity and mortality, and significant economic and quality of life impact. Even after the recovery phase, the development and persistence of sequelae from the inflammatory/necrotic process, including exocrine and endocrine pancreatic insufficiencies, are frequent. Although well documented as consequence of other pancreatic conditions, exocrine pancreatic insufficiency (EPI) after acute pancreatitis is poorly studied and probably underdiagnosed. The prevalence, diagnosis, independent risk factors and therapeutic approaches for EPI after acute pancreatitis need further investigation. Recent evidence suggests the involvement of the pancreas-intestinal axis and immunological dysfunction in several pancreatic pathologies, although their role in the development of EPI after acute pancreatitis is still scarce. Pancreatic enzyme replacement therapy (PERT) is the only treatment currently available in EPI, but the timing for start and duration of this therapy in acute pancreatitis remain to be established. This study have the following objectives: to determine the prevalence, clinical, analytical and nutritional biomarkers and duration of EPI after acute pancreatitis, as well as changes in gut microbiota and immunologic response, and quality of life in EPI and response to PERT after acute pancreatitis; and to determine the prevalence and biomarkers associated with endocrine pancreatic insufficiency following acute pancreatitis and the presence of gut dysbiosis and immunologic changes in acute pancreatitis according to its severity.


Description:

Read more »
Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pancreatic Enzyme Replacement Therapy
Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting
Placebo
Placebo + Omeprazole 20mg once daily on fasting

Locations

Country Name City State
Portugal Centro Hospitalar e Universitário de Coimbra, E.P.E. Coimbra

Sponsors (2)

Lead Sponsor Collaborator
Centro Hospitalar e Universitário de Coimbra, E.P.E. University of Coimbra

Country where clinical trial is conducted

Portugal, 

References & Publications (29)

See more »

Outcome

Type Measure Description Time frame Safety issue
Primary When to start PERT assessed by the time, in days, between acute pancreatitis diagnosis and EPI diagnosis in patients with EPI following acute pancreatitis A standardized protocol will be applied for both groups differing only in drug used (PERT or placebo).
To evaluate when to start PERT we will determine the time between acute pancreatitis diagnosis and EPI diagnosis, in days. Searching for EPI will take place up to 12 months after acute pancreatitis diagnosis.
Up to 12 months
Primary PERT efficacy assessed by % of successful treatments in patients with EPI following acute pancreatitis A standardized protocol will be applied for both groups differing only in drug used (PERT or placebo). The PERT dose will be the one agreed for EPI for benign pancreatic pathologies associated with proton pump inhibitor (PPI).
PERT efficacy will be assessed by the % of successful treatments in patients with EPI diagnosis after acute pancreatitis, using the test that was positive for EPI diagnosis (fecal elastase-1, 13 C Mixed Triglyceride Breath Test or Fecal Fat Quantitative Test). Efficacy corresponds to the normalization of exocrine pancreatic function test and will be assessed by at 6 months post-randomization. The compliance of PERT will be checked in all follow-up visits.
At 6 months after starting PERT
Primary PERT safety assessed by adverse effects according to Medical Dictionary for Regulatory Activities in patients with EPI following acute pancreatitis A standardized protocol will be applied for both groups differing only in drug used (PERT or placebo). The PERT dose will be the one agreed for EPI for benign pancreatic pathologies associated with proton pump inhibitor (PPI).
PERT safety will be evaluated with the determination of adverse effects according to Medical Dictionary for Regulatory Activities (MedDRa will be evaluated in terms of visual analogic intolerance scale (0-10) for abdominal pain and other adverse events severity in relation to the influence on activities of daily life. PERT safety will be assessed at 6 months post-randomization. The compliance of PERT will be checked in all follow-up visits.
At 6 months after starting PERT
Primary PERT duration assessed by the time of starting PERT to normalization of exocrine pancreatic function in patients with EPI following acute pancreatitis A standardized protocol will be applied for both groups differing only in drug used (PERT or placebo). The PERT dose will be the one agreed for EPI for benign pancreatic pathologies associated with proton pump inhibitor (PPI).
The duration of PERT will be evaluated determining the time, in months, between EPI diagnosis after acute pancreatitis diagnosis and the normalization of exocrine pancreatic function, determined by the normalization of positive test diagnosing EPI (fecal elastase-1, 13 C Mixed Triglyceride Breath Test or Fecal Fat Quantitative Test), using the test that was positive for EPI diagnosis.
At 6 months after starting PERT
Secondary Prevalence of exocrine pancreatic insufficiency (EPI) following acute pancreatitis assessed by the proportion and percentage of patients with EPI after acute pancreatitis diagnosis After the recruitment of eligible patients with the first episode of acute pancreatitis, they will be stratified according to acute pancreatitis severity and EPI development. Acute pancreatitis severity will be classified into mild, moderately severe and severe cases according to the revised criteria of Atlanta 2012. The EPI diagnosis will be performed by noninvasive 13C-labeled mixed triglyceride breath test and by the non-invasive fecal elastase-1 test. At diagnosis, 72-hour fecal fat quantification will also be used as a validated indirect gold standard test.
The prevalence of EPI will be determined by the proportion and percentage of patients with each of these complications to the total of patients with acute pancreatitis during 12-month follow-up after acute pancreatitis diagnosis. Searching for EPI will take place up to 12 months after acute pancreatitis diagnosis.
Up to 12 months
Secondary Prevalence of endocrine pancreatic insufficiency (EnPI) following acute pancreatitis assessed by the proportion and % of patients with EnPI after acute pancreatitis diagnosis After the recruitment of eligible patients with the first episode of acute pancreatitis, they will be stratified according to acute pancreatitis severity and EPI development. Acute pancreatitis severity will be classified into mild, moderately severe and severe cases according to the revised criteria of Atlanta 2012. Assessment of EnPI (secondary endpoint) will be defined by the development of new-onset pre-diabetes and/or diabetes mellitus - type 3 diabetes mellitus according to the diagnostic criteria of the American Diabetes Association 2019.
The prevalence of EnPI will be determined by the proportion and percentage of patients with each of these complications to the total of patients with acute pancreatitis during 12-month follow-up after acute pancreatitis diagnosis.
Up to 12 months
Secondary Changes in gut microbiota profile using DNA sequencing of ribosomal 16S bacteria gene in acute pancreatitis, EPI following acute pancreatitis and after PERT assessed by the changes in composition and diversity of gut microbiota (OTU changes) Analysis of gut microbiota by DNA sequencing using the hypervariable region of the ribosomal 16S bacteria gene as a taxonomic identification marker and quality of life assessment: Gut microbiota will be assessed for a number of species present (richness) and qualitative composition (diversity and uniformity) using next-generation genome sequencing techniques by an independent operator who will not know the status and therapy of EPI (PERT vs placebo). After extraction of the bacterial DNA, the sequencing of the gut microbiota by bioinformatic analysis will be performed for taxonomic identification and determination of the relative abundance of each Operational Taxonomy Units (OTU). Gut microbiota will be evaluated at baseline (acute pancreatitis diagnosis), at EPI diagnosis and 6 months after starting PERT. Change from Baseline at 6 months after starting PERT
Secondary Changes in Immunological profile assessed by study of cell populations in acute pancreatitis, EPI following acute pancreatitis diagnosis and after PERT To evaluate the role of immunological response in EPI post-acute pancreatitis and PERT response, fresh peripheral blood samples will be collected and processed until obtain serum by centrifugation at 4ºC and stored at -20°C and then analyzed after the diagnosis of acute pancreatitis, after diagnosis of EPI and 6months after PERT. A standard protocol with be followed. Analysis of immunological changes: Immunological profile will be analyzed through the study of cell populations (CD4+, CD8+, B-cell, T-cell, natural killer cells, cells ratio) by multiparametric flow cytometry at acute pancreatitis diagnosis, immediately after EPI diagnosis and 6 months after PERT. This analysis will be performed by an independent operator who will not know the status and therapy of EPI (PERT vs placebo). Change from Baseline at 6 months after starting PERT
Secondary Changes in quality of life in patients with EPI after acute pancreatitis, EPI following acute pancreatitis and after PERT assessed by quality of life scale appropriated to this condition - SF-36 The quality of life will be measured through the scale SF-36, validated for the Portuguese population and applicable to this pathology, that will take place after the diagnosis of acute pancreatitis, after diagnosis of EPI and 6 months after PERT. It is a 36-item questionnaire. All ofthe scales and single item scales range in score from 0 to 100. A high score for global health status/QoL represents high/healthy level of functioning and QoL. Change from Baseline at 6 months after starting PERT
Secondary Post-PERT changes assessed by cytokines, chemokines and growth factors in immunological profile Fresh peripheral blood samples will be collected and processed until obtain serum by centrifugation at 4ºC and stored at -20°C and then analyzed after the diagnosis of acute pancreatitis, after diagnosis of EPI and 6months after PERT. A standard protocol with the conditions of collection, storage and transport of the different collected samples will be used. Changes from Baseline in immunological profile on cytokines, chemokines and growth factors by xMAP/Luminex at 6 months post-PERT. This analysis will be performed by an independent operator who will not know the status and therapy of EPI (PERT vs placebo). Change from Baseline at 6 months after starting PERT
Secondary Changes in quality of life in patients with EPI after acute pancreatitis, EPI following acute pancreatitis and after PERT assessed by quality of life scale appropriated to this condition - QLC-C30-V.3.0 The quality of life will be measured through the scale QLC-C30-V.3.0, validated for the Portuguese population and applicable to this pathology, that will take place after the diagnosis of acute pancreatitis, after diagnosis of EPI and 6 months after PERT. It is a 30-item questionnaire. All ofthe scales and single item scales range in score from 0 to 100. A high score for functional scales and global health status/QoL represents high/healthy level of functioning and QoL. A high score for a symptom scale/item represents a high level of symptomatology or problems. Change from Baseline at 6 months after starting PERT
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05410795 - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Recruiting NCT04195347 - Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase Phase 1/Phase 2
Completed NCT04735055 - Artificial Intelligence Prediction for the Severity of Acute Pancreatitis
Completed NCT02928718 - The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations
Terminated NCT02885441 - Treatment of Acute Pancreatitis With Ketorolac Phase 4
Completed NCT02563080 - Pancreatic Exocrine Insufficiency in Acute Pancreatitis
Recruiting NCT01626911 - Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis N/A
Completed NCT01507766 - The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis Phase 4
Completed NCT04901949 - The Course of Acute Pancreatitis in Patients With Different BMI Groups
Recruiting NCT04814693 - Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis N/A
Completed NCT02743364 - Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis Phase 2
Recruiting NCT05281458 - Early Versus Standard Endoscopic Interventions for Peripancreatic Fluid Collections N/A
Not yet recruiting NCT04990336 - Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis N/A
Not yet recruiting NCT03259880 - Searching the Best Prognostic Factor in Out Come Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals N/A
Completed NCT02543658 - Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension Phase 2
Recruiting NCT06023771 - Invasive Intervention of Local Complications of Acute Pancreatitis
Not yet recruiting NCT05501314 - Remote Home Monitoring Acute Pancreatitis N/A
Completed NCT02897206 - Imipenem Prophylaxis in Patients With Acute Pancreatitis Phase 4
Recruiting NCT03634787 - Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis
Active, not recruiting NCT04989166 - Effect of Nano-curcumin Supplementation in Acute Pancreatitis N/A